A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression.

This study will treat up to 10 participants. The primary objective is to characterize central nervous system (CNS) penetration of KYV-101 and its effectiveness of target engagement via elimination of oligoclonal bands (OCB) and/or normalization of immunoglobulin G (IgG) IgG index and to characterize a preliminary safety profile of KYV-101 in treatment-refractory MS.

Sponsor

Bruce Cree, MD, PhD, MAS, University of California, San Francisco

Status of enrollment

Accepting new patients

Ages Eligible for Study

Adults aged 25 - 70 years old

Genders Eligible for Study

Female and Male

Disease Indication

Progressive Multiple Sclerosis

Principal Investigator

Bruce Cree, MD, PhD, MAS

Contact

Robin Lincoln

[email protected]

415-502-7216

Additional study eligibility details can be found at UCSF Clinical Trials.